PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (HGH SUPPORT)
DRUG NAME: CJC-1295

• FDA Safety Data Sheet not available (experimental peptide therapy)

• Sigalos J. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 [PubMed Link] 

• Sinha DK. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 [PubMed Link]

• Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 [PubMed Link]

• Svensson J. Growth hormone secretagogues as therapeutic agents. Growth Horm IGF Res. 1999 [PubMed Link]

• Sigalos JT. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 [PubMed Link]

• Ferro P. Structure-activity relationship for peptídic growth hormone secretagogues. Drug Test Anal. 2017 [PubMed Link]

• Thomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012 [PubMed Link]

• Peschke B. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. Eur J Med Chem. 2002 [PubMed Link] 

• Lall S. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001 [PubMed Link] 

• Johansen PB. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 [PubMed Link]

• Teichman S. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 [PubMed Link]

• Ionescu M. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 [PubMed Link]